The company posted adjusted earnings of $2.77 per share on revenue of $21.9 billion, exceeding consensus estimates of $2.59 per share and $21.6 billion in revenue.

Despite premarket gains, shares of AnaptysBio (NASDAQ:ANAB) turned lower on Wednesday following disappointing mid-stage trial data for Johnson & Johnson’s (NYSE:JNJ) anti-inflammatory agent JNJ ...

In early trading on Friday, shares of Johnson & Johnson ( JNJ) topped the list of the day's best performing Dow Jones Industrial Average components, trading up 0.2%. Year to date, Johnson ...

J&J (JNJ -0.5%) is exploring the options for its Ortho Clinical Diagnostics (OCD) unit, including a divestiture if "it is determined that OCD could ...

The latest tally of analyst opinions from the major brokerage houses shows that among the 30 stocks making up the Dow Jones Industrial Average, Johnson & Johnson is the #17 analyst pick. Within ...

JNJ beat Q4 estimates for both earnings and sales, with earnings of $2.04 per share and $22.5 billion in sales. The FDA granted approval to AstraZeneca/Daiichi's Dato-DXd for previously treated ...

PARIS and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering ...

Essential stuff indeed, particularly for OCD-prone customers. A full set of four caps retails at £156 (approximately $194) and is compatible with vehicles whose alloy wheels are able to accept ...